TGFB1 and chronic kidney disease: In an in vitro experiment, MDL-800 decreased the TGF-β1-induced activation of myofibroblasts and ECM production by regulating SIRT6-dependent β-catenin acetylation and the TGF-β1/Smad signaling pathway.907 The identification of strategies to prevent and/or treat fibrotic CKD is a daunting challenge, and no treatment is specifically targeted at kidney fibrosis.908 The effects of the SIRT protein family on the TGF-β signaling pathway may identify new targets for therapeutic intervention in kidney fibrosis.